Villanova Investment Management Co LLC Trims Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Villanova Investment Management Co LLC reduced its position in Supernus Pharmaceuticals by 65.7%, leaving them with 19,587 shares valued at approximately $641,000.
• Several other hedge funds have modified their stakes in Supernus, with Armistice Capital LLC increasing its holdings by 7.4% to 5.2 million shares valued at $170.2 million.
• Supernus Pharmaceuticals received upgraded ratings from Wall Street firms, with Cantor Fitzgerald raising its price objective from $42.00 to $46.00 and two analysts rating the stock as a Buy.

Villanova Investment Management Co LLC lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 65.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,587 shares of the specialty pharmaceutical company's stock after selling 37,445 shares during the period. Supernus Pharmaceuticals comprises about 1.8% of Villanova Investment Management Co LLC's holdings, making the stock its 22nd biggest position. Villanova Investment Management Co LLC's holdings in Supernus Pharmaceuticals were worth $641,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in SUPN. Captrust Financial Advisors increased its holdings in Supernus Pharmaceuticals by 84.6% during the fourth quarter. Captrust Financial Advisors now owns 17,394 shares of the specialty pharmaceutical company's stock worth $629,000 after buying an additional 7,969 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Supernus Pharmaceuticals by 226.2% in the fourth quarter. Deutsche Bank AG now owns 105,583 shares of the specialty pharmaceutical company's stock worth $3,818,000 after purchasing an additional 73,213 shares in the last quarter. Graham Capital Management L.P. purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $250,000. Gotham Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 3.8% in the fourth quarter. Gotham Asset Management LLC now owns 39,212 shares of the specialty pharmaceutical company's stock worth $1,418,000 after purchasing an additional 1,419 shares in the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $890,000.

Supernus Pharmaceuticals Trading Down 0.4%

Shares of SUPN traded down $0.19 during mid-day trading on Tuesday, reaching $43.80. The company's stock had a trading volume of 235,900 shares, compared to its average volume of 635,734. The stock has a market cap of $2.46 billion, a PE ratio of 38.09 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $46.78. The company's fifty day moving average price is $39.67 and its two-hundred day moving average price is $34.70.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald lifted their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Piper Sandler lifted their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research note on Friday, August 29th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $43.00.

Insider Buying and Selling

In related news, Director Frederick M. Hudson sold 7,457 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total value of $315,132.82. Following the transaction, the director directly owned 46,307 shares of the company's stock, valued at $1,956,933.82. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Frank Mottola sold 14,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, August 25th. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $689,726.96. The trade was a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 246,506 shares of company stock valued at $10,696,144 over the last quarter. Company insiders own 8.80% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.